Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Eymard

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|March 5, 2002
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trialM Spielmann, M Tubiana-Hulin, M Namer, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2007
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancerJ-C Eymard, F Priou, A Zannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?R Sabatier, J C Eymard, J Walz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trialK Fizazi, G Gravis, A Flechon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 1998
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II studyT D Nguyen, S Theobald, P Rougier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerI Treilleux, M Arnedos, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinomaR Elaidi, A Harbaoui, B Beuselinck, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
British Journal of Cancer|May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trialP Kerbrat, H Roché, J Bonneterre, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|March 5, 2002
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trialM Spielmann, M Tubiana-Hulin, M Namer, et al.
Prostate Cancer and Prostatic Diseases|October 15, 2014
Who dies from prostate cancer?A Patrikidou, Y Loriot, J-C Eymard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 17, 2007
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancerJ-C Eymard, F Priou, A Zannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?R Sabatier, J C Eymard, J Walz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2014
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trialK Fizazi, G Gravis, A Flechon, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 10, 1998
Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II studyT D Nguyen, S Theobald, P Rougier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancerI Treilleux, M Arnedos, C Cropet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinomaR Elaidi, A Harbaoui, B Beuselinck, et al.
The Journal of Urology|August 21, 2002
Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer CentersB Escudier, J P Droz, F Rolland, et al.
British Journal of Cancer|May 17, 2007
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trialP Kerbrat, H Roché, J Bonneterre, et al.
Pageof 4